Natixis Advisors LLC Sells 58,936 Shares of Moderna, Inc. (NASDAQ:MRNA)

Natixis Advisors LLC lowered its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 83.6% during the 3rd quarter, according to its most recent filing with the SEC. The firm owned 11,574 shares of the company’s stock after selling 58,936 shares during the period. Natixis Advisors LLC’s holdings in Moderna were worth $773,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Empowered Funds LLC lifted its stake in Moderna by 6.6% during the 3rd quarter. Empowered Funds LLC now owns 5,199 shares of the company’s stock valued at $347,000 after acquiring an additional 322 shares during the period. Empirical Finance LLC increased its position in shares of Moderna by 4.0% during the 3rd quarter. Empirical Finance LLC now owns 8,613 shares of the company’s stock valued at $576,000 after purchasing an additional 334 shares during the last quarter. CIBC Asset Management Inc increased its position in shares of Moderna by 6.3% during the 3rd quarter. CIBC Asset Management Inc now owns 113,822 shares of the company’s stock valued at $7,607,000 after purchasing an additional 6,794 shares during the last quarter. Tokio Marine Asset Management Co. Ltd. increased its position in shares of Moderna by 14.8% during the 3rd quarter. Tokio Marine Asset Management Co. Ltd. now owns 10,784 shares of the company’s stock valued at $721,000 after purchasing an additional 1,387 shares during the last quarter. Finally, Metis Global Partners LLC increased its position in shares of Moderna by 13.9% during the 3rd quarter. Metis Global Partners LLC now owns 14,834 shares of the company’s stock valued at $991,000 after purchasing an additional 1,814 shares during the last quarter. Institutional investors own 75.33% of the company’s stock.

Moderna Trading Up 3.2 %

Shares of MRNA opened at $43.39 on Thursday. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.39 and a quick ratio of 4.20. Moderna, Inc. has a 1 year low of $35.80 and a 1 year high of $170.47. The company has a 50 day simple moving average of $53.32 and a two-hundred day simple moving average of $92.28. The firm has a market cap of $16.70 billion, a P/E ratio of -7.46 and a beta of 1.69.

Moderna (NASDAQ:MRNA) last posted its earnings results on Thursday, November 7th. The company reported $0.03 EPS for the quarter, beating analysts’ consensus estimates of ($1.89) by $1.92. The firm had revenue of $1.90 billion during the quarter, compared to the consensus estimate of $1.25 billion. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The company’s quarterly revenue was up 3.8% compared to the same quarter last year. During the same period in the prior year, the company earned ($1.39) EPS. On average, equities analysts expect that Moderna, Inc. will post -9.44 earnings per share for the current fiscal year.

Analysts Set New Price Targets

MRNA has been the subject of several research reports. UBS Group reduced their price target on shares of Moderna from $140.00 to $108.00 and set a “buy” rating for the company in a research report on Thursday, October 24th. JPMorgan Chase & Co. reduced their target price on shares of Moderna from $59.00 to $45.00 and set an “underweight” rating for the company in a report on Tuesday. Piper Sandler reissued an “overweight” rating and issued a $69.00 target price (down from $115.00) on shares of Moderna in a report on Monday, November 18th. Hsbc Global Res raised shares of Moderna from a “hold” rating to a “strong-buy” rating in a report on Monday, November 18th. Finally, Wolfe Research started coverage on shares of Moderna in a report on Friday, November 15th. They issued an “underperform” rating and a $40.00 target price for the company. Three investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $83.26.

Insider Activity

In other news, CFO James M. Mock sold 715 shares of the stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $60.12, for a total transaction of $42,985.80. Following the completion of the transaction, the chief financial officer now directly owns 9,505 shares in the company, valued at approximately $571,440.60. This represents a 7.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last ninety days, insiders sold 1,147 shares of company stock worth $76,245. 15.70% of the stock is currently owned by insiders.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.